Available Technologies

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

Find technologies available for licensing from UCSF.

Novel microbial species that promote fetal tolerogenic immunity

New therapies to prevent the development of asthma and other chronic inflammatory diseases in infants using natural bacterial modulators of fetal immune development.

Neoantigen-specific antibodies for chemically directed immune targeting of KRAS tumors

UCSF scientists have discovered novel antibodies that can specifically and selectively recognize tumor-derived neoantigens. The antibodies can be used for IgG, BiTE or CAR-T-based targeted immunotherapy and small molecule-based directed immune targeting via combination therapy. This dual therapeutic approach has the potential to specifically recognize and treat KRAS (G12C) cancer cell populations with high specificity, significantly improve cancer treatment outcomes, and overcome risk of treatment resistance in patients.

Fragment-Based Stabilization Of 14-3-3/Client Protein-Protein Interactions

UCSF and Technical University of Eindhoven investigators have identified molecular fragments that stabilize 14-3-3/phospho-peptide and 14-3-3/phospho-protein interactions.  Further structure-guided and empirical medicinal chemistry will lead to a drug lead for the most advanced target (estrogen receptor).   

IFN-gamma Receptor On T Cell Immunotherapy

This invention identifies that tumor-specific T cells are susceptible to immunotherapy induced IFN-gamma toxicity in low tumor burden circumstances, and provides a novel method for rescuing those tumor-reactive T cells and anti-tumor immunity through disruption of IFN-gamma signaling.

Kelch Like Family Member 11 (Klhl11) Autoantibodies As Markers Of Seminoma Associated Paraneoplastic Encephalitis In Men

Researchers at UCSF and Chan Zuckerberg Biohub have discovered a novel biomarker for an autoimmune disease that affects patients with testicular cancer.  The disease, known as “testicular cancer-associated paraneoplastic encephalitis,” can cause severe neurological symptoms.  The symptoms include loss of limb control, eye movement, and in some cases, speech.  The disease begins with testicular cancer, which in some cases causes the immune system to attack the brain.  Affected patients are often misdiagnosed and appropriate treatment is delayed. 

Urine Metabolomics For Identification Of Novel Biomarkers For Transplant Injury

This invention discloses a method for the non-invasive detection of renal allograft injuries–acute rejection, BK virus, and/or chronic allograft nephropathy–via a panel of novel biomarkers. 

Novel small molecule drugs for the treatment of sleep disorders and depression

UCSF scientists have identified novel small molecules which are selective agonists and inverse agonists of the melatonin receptor types MT1 and MT2. The molecules have high in vitro and in vivo potency and potential to be utilized as a novel therapeutic for treating depression, jet lag, and sleep disorders.

Chemical Modulators of Nurr1

Long thought to be undruggable, Nurr1 is a nuclear receptor and transcription factor involved in the development, maintenance, and survival of midbrain dopaminergic neurons, which makes it an attractive target for developing therapeutics for such indications of Parkinson’s disease, multiple sclerosis, and schitzophrenia.